19 March 2025
Breaking News: Fotona Secures NMPA Approval for IncontiLase® in China!
Fotona has made history as the first laser company to receive NMPA approval in China for the treatment of mild and moderate SUI.
Read more
Highest level medical evidence proving the efficacy and safety of Fotona SMOOTH® modality for treatment of Stress Urinary Incontinence (SUI)
18 October 2021
Key opinion leader Dr. Barry O'Reilly has presented the results of a multicentric randomized controlled trial of Fotona's IncontiLase treatment at this year's ICS Conference.
The results show that IncontiLase® performs significantly better than sham treatment in reducing the symptoms of SUI. The trial included 8 prominent European urogynecological investigators from the UK, Ireland, Switzerland, Greece and Slovenia, which were coordinated by Dr. Barry O'Reilly from Ireland.
Although it is not the first RCT for IncontiLase®, it is significant because it was the first multicentric trial and also included the widest array of objective and subjective measures, with up to 1 year follow up. The study provides the highest-level medical evidence of the efficacy and safety of the Fotona SMOOTH® laser modality for the treatment of stress urinary incontinence.
For more information see the abstract or watch Dr. O'Reilly's lecture at the ICS conference.
Related news
15 May 2025
LA&HA Celebrates Successful Launch of Two New Medical Laser Training Centres in Latin America
The new training centres in Colombia and Mexico will offer specialized workshops in aesthetics and gynecology, supported by experienced local doctors and LA&HA faculty.
Read more
3 November 2025
Fotona APAC 2025: A Celebration of Innovation, Learning, and Connection
The 11th Fotona Asia Pacific Meeting (APAC 2025) in Melbourne, Australia, was an unforgettable gathering of laser experts, clinicians, and partners from around the globe.
Read more
